array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(26) "Bio-RAD Laboratories, Inc."
["slug"]=>
string(33) "001cd-us-bio-rad-laboratories-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/9d1c28c2-1b47-4093-8ed2-5151f3fe7920"
["description"]=>
string(867) "Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.
#Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics"
["address_street"]=>
string(20) "1000 Alfred Nobel Dr"
["address_place"]=>
string(8) "Hercules"
["address_region"]=>
string(10) "California"
["founding_date"]=>
string(10) "1952-02-08"
["website_domain"]=>
string(11) "bio-rad.com"
["website_url"]=>
string(23) "https://www.bio-rad.com"
["industry_codes"]=>
array(3) {
[0]=>
string(42) "In Vitro and In Vivo Diagnostic Substances"
[1]=>
string(33) "Laboratory Analytical Instruments"
[2]=>
string(47) "Electromedical and Electrotherapeutic Apparatus"
}
["employee_count"]=>
int(7900)
["article_count"]=>
int(661)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(73) "Scope Fluidics (WSE:SCP) - Stock Price, News & Analysis - Simply Wall St"
["snippet_en"]=>
string(155) "Research Scope Fluidics' (WSE:SCP) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more."
["url"]=>
string(72) "https://simplywall.st/stocks/pl/healthcare/wse-scp/scope-fluidics-shares"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/6d70ed64-378e-46e9-bb90-37dead2c5896"
["source"]=>
string(13) "simplywall.st"
["publication_date"]=>
string(10) "2024-02-26"
["categories"]=>
array(5) {
[0]=>
string(12) "Stock Market"
[1]=>
string(18) "General Investment"
[2]=>
string(24) "Stock Research & Ratings"
[3]=>
string(15) "Market Movement"
[4]=>
string(9) "Valuation"
}
}
[1]=>
array(7) {
["title_en"]=>
string(80) "Bio-Rad Laboratories (NYSE:BIO) - Stock Price, News & Analysis - Simply Wall St"
["snippet_en"]=>
string(162) "Research Bio-Rad Laboratories' (NYSE:BIO) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more."
["url"]=>
string(85) "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/8141cc14-f185-4b4b-8269-b0c9b83caef8"
["source"]=>
string(13) "simplywall.st"
["publication_date"]=>
string(10) "2024-01-24"
["categories"]=>
array(5) {
[0]=>
string(12) "Stock Market"
[1]=>
string(10) "Executives"
[2]=>
string(12) "Board Change"
[3]=>
string(24) "Stock Research & Ratings"
[4]=>
string(15) "Market Movement"
}
}
[2]=>
array(7) {
["title_en"]=>
string(84) "Zacks Research Weighs in on Bio-Rad Laboratories, Inc.'s Q1 2025 Earnings (NYSE:BIO)"
["snippet_en"]=>
string(300) "Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Stock analysts at Zacks Research cut their Q1 2025 EPS estimates for Bio-Rad Laboratories in a research note issued to investors on Tuesday, January 16th. Zacks Research analyst R. Anand now forecasts that the medical research company will pos"
["url"]=>
string(89) "https://www.marketbeat.com/instant-alerts/nyse-bio-analyst-earnings-estimates-2024-01-19/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/4c2cc902-3ad5-47d1-82b6-b5f42dbe6540"
["source"]=>
string(14) "marketbeat.com"
["publication_date"]=>
string(10) "2024-01-19"
["categories"]=>
array(7) {
[0]=>
string(12) "Stock Market"
[1]=>
string(13) "Credit Rating"
[2]=>
string(5) "R & D"
[3]=>
string(9) "Investors"
[4]=>
string(24) "Quarterly/Annual Figures"
[5]=>
string(24) "Stock Research & Ratings"
[6]=>
string(17) "Academic Research"
}
}
[3]=>
array(7) {
["title_en"]=>
string(45) "Scope Fluidics: Turning micro-flows into cash"
["snippet_en"]=>
string(277) "We are starting to issue recommendations for Scope Fluidics with a BUY recommendation and a fair value valuation of PLN 235.8/share (42% growth potential compared to the current price). Scope Fluidics became a role model among Polish medtech start-ups after the sale of PCR|ONE"
["url"]=>
string(79) "https://www.fxmag.pl/artykul/scope-fluidics-zmieniajac-mikroprzeplywy-w-gotowke"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/89884aa2-69dc-4b21-86ef-787a1ffc3db2"
["source"]=>
string(8) "fxmag.pl"
["publication_date"]=>
string(10) "2023-11-10"
["categories"]=>
array(4) {
[0]=>
string(10) "Divestment"
[1]=>
string(9) "Valuation"
[2]=>
string(25) "Start-up's & New Business"
[3]=>
string(24) "Stock Research & Ratings"
}
}
[4]=>
array(7) {
["title_en"]=>
string(52) "Bio-Rad Shares Drop After Company Reports 3Q Results"
["snippet_en"]=>
string(160) "By Stephen Nakrosis Shares of Bio-Rad Laboratories were trading lower in the after-hours market following the release of third-quarter financial results that..."
["url"]=>
string(95) "https://www.marketwatch.com/story/bio-rad-shares-drop-after-company-reports-3q-results-0d9c70ab"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/3bebe02f-4333-46c5-bde4-e8e5d9bb24c2"
["source"]=>
string(15) "marketwatch.com"
["publication_date"]=>
string(10) "2023-10-26"
["categories"]=>
array(7) {
[0]=>
string(31) "Financial Update/Profit Warning"
[1]=>
string(12) "Stock Market"
[2]=>
string(21) "Financial Performance"
[3]=>
string(24) "Quarterly/Annual Figures"
[4]=>
string(14) "Issuing Shares"
[5]=>
string(24) "Stock Research & Ratings"
[6]=>
string(15) "Market Movement"
}
}
[5]=>
array(7) {
["title_en"]=>
string(80) "HighTower Advisors LLC Sells 142 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)"
["snippet_en"]=>
string(217) "HighTower Advisors LLC reduced its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 2.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission."
["url"]=>
string(119) "http://www.defenseworld.net/2023/09/08/hightower-advisors-llc-sells-142-shares-of-bio-rad-laboratories-inc-nysebio.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/70bb08f6-8b4a-443a-8583-9cc819a13978"
["source"]=>
string(16) "defenseworld.net"
["publication_date"]=>
string(10) "2023-09-08"
["categories"]=>
array(8) {
[0]=>
string(31) "Financial Update/Profit Warning"
[1]=>
string(12) "Stock Market"
[2]=>
string(10) "Divestment"
[3]=>
string(18) "General Investment"
[4]=>
string(24) "Quarterly/Annual Figures"
[5]=>
string(14) "Issuing Shares"
[6]=>
string(24) "Stock Research & Ratings"
[7]=>
string(9) "Valuation"
}
}
[6]=>
array(7) {
["title_en"]=>
string(82) "Timothy S. Ernst Sells 2,350 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock"
["snippet_en"]=>
string(252) "Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) EVP Timothy S. Ernst sold 2,350 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $395.60, for a total value of $929,660.00."
["url"]=>
string(119) "http://www.defenseworld.net/2023/09/02/timothy-s-ernst-sells-2350-shares-of-bio-rad-laboratories-inc-nysebio-stock.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/dfacb159-fe6e-4a94-bd88-9bc8949d674e"
["source"]=>
string(16) "defenseworld.net"
["publication_date"]=>
string(10) "2023-09-02"
["categories"]=>
array(5) {
[0]=>
string(12) "Stock Market"
[1]=>
string(10) "Divestment"
[2]=>
string(24) "Quarterly/Annual Figures"
[3]=>
string(14) "Issuing Shares"
[4]=>
string(24) "Stock Research & Ratings"
}
}
[7]=>
array(7) {
["title_en"]=>
string(95) "American Century Companies Inc. Acquires 34,008 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)"
["snippet_en"]=>
string(231) "American Century Companies Inc. grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 261.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission."
["url"]=>
string(132) "http://www.defenseworld.net/2023/08/31/american-century-companies-inc-acquires-34008-shares-of-bio-rad-laboratories-inc-nysebio.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/6d5bd8ea-cdf3-4c11-9ab8-b487869e91d0"
["source"]=>
string(16) "defenseworld.net"
["publication_date"]=>
string(10) "2023-08-31"
["categories"]=>
array(8) {
[0]=>
string(31) "Financial Update/Profit Warning"
[1]=>
string(13) "Credit Rating"
[2]=>
string(12) "Stock Market"
[3]=>
string(18) "General Investment"
[4]=>
string(24) "Quarterly/Annual Figures"
[5]=>
string(11) "Acquisition"
[6]=>
string(14) "Issuing Shares"
[7]=>
string(24) "Stock Research & Ratings"
}
}
[8]=>
array(7) {
["title_en"]=>
string(128) "S&P 500 paper Bio-Rad Laboratories stock: This is how much of a loss an early Bio-Rad Laboratories investment would have yielded"
["snippet_en"]=>
string(86) "Investors would have lost so much by investing in Bio-Rad Laboratories stock early on."
["url"]=>
string(174) "https://www.finanzen.ch/nachrichten/aktien/s-p-500-papier-bio-rad-laboratories-aktie-so-viel-verlust-haette-ein-fruehes-bio-rad-laboratories-investment-eingebracht-1032586242"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/665de5fc-a62e-45de-84b9-f1bf903d1e3c"
["source"]=>
string(11) "finanzen.ch"
["publication_date"]=>
string(10) "2023-08-28"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(18) "General Investment"
[2]=>
string(24) "Stock Research & Ratings"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(66)
}
[1]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(51)
}
[2]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(31)
}
[3]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(28)
}
[4]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(26)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(24)
}
[6]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(23)
}
[7]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(20)
}
[8]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(19)
}
[9]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(19)
}
[10]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(19)
}
[11]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(18)
}
[12]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(14)
}
[13]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(14)
}
[14]=>
array(2) {
["name"]=>
string(18) "Ecological Impacts"
["count"]=>
int(13)
}
[15]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(13)
}
[16]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(9)
}
[17]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(9)
}
[18]=>
array(2) {
["name"]=>
string(10) "New Market"
["count"]=>
int(9)
}
[19]=>
array(2) {
["name"]=>
string(11) "Regulations"
["count"]=>
int(9)
}
[20]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(8)
}
[21]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(7)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(7)
}
[23]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(7)
}
[24]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(7)
}
[25]=>
array(2) {
["name"]=>
string(16) "Case Settlements"
["count"]=>
int(6)
}
[26]=>
array(2) {
["name"]=>
string(13) "Credit Rating"
["count"]=>
int(5)
}
[27]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(5)
}
[28]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(5)
}
[29]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(5)
}
}
}
001cd-us-bio-rad-laboratories-inc
Bio-RAD Laboratories, Inc.
Location
California
Founded
1952-02-08
Website
https://www.bio-rad.com
Articles
661 Articles
Category
In Vitro and In Vivo Diagnostic Substances
Laboratory Analytical Instruments
Electromedical and Electrotherapeutic Apparatus
Description
Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.
#Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics
Research Scope Fluidics' (WSE:SCP) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more.
Research Bio-Rad Laboratories' (NYSE:BIO) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more.
Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Stock analysts at Zacks Research cut their Q1 2025 EPS estimates for Bio-Rad Laboratories in a research note issued to investors on Tuesday, January 16th. Zacks Research analyst R. Anand now forecasts that the medical research company will pos
We are starting to issue recommendations for Scope Fluidics with a BUY recommendation and a fair value valuation of PLN 235.8/share (42% growth potential compared to the current price). Scope Fluidics became a role model among Polish medtech start-ups after the sale of PCR|ONE
By Stephen Nakrosis Shares of Bio-Rad Laboratories were trading lower in the after-hours market following the release of third-quarter financial results that...
HighTower Advisors LLC reduced its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 2.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission.
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) EVP Timothy S. Ernst sold 2,350 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $395.60, for a total value of $929,660.00.
American Century Companies Inc. grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 261.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.